Third Harmonic Bio, Inc. reported a net loss of $15.834 million for the three months ended March 31, 2025, an increase from $7.856 million in the same period last year. The company's total operating expenses significantly increased to $18.716 million, primarily driven by higher research and development costs.
Net loss increased to $15.834 million in Q1 2025 from $7.856 million in Q1 2024.
Total operating expenses rose to $18.716 million in Q1 2025 from $11.290 million in Q1 2024, a 66% increase.
Research and development expenses increased by 71% to $10.645 million in Q1 2025, mainly due to the THB335 program.
General and administrative expenses increased by 59% to $8.071 million in Q1 2025, driven by personnel-related expenses and stock-based compensation.
The company expects its existing cash and cash equivalents to be sufficient to fund operations and capital expenses through at least 2026, subject to stockholder approval of the Dissolution and Plan of Dissolution. They plan to complete Phase 2 readiness activities for THB335 by mid-year 2025 to maximize its value for a potential asset sale.